Drug and alcohol screening is a process that analyzes a biological sample, most commonly urine, to detect the presence of specific substances in your body. It’s used in workplaces, clinical settings, legal proceedings, and addiction treatment programs to determine whether someone has recently used drugs or alcohol. Most screenings follow a two-step approach: a quick initial test flags potential positives, and a more precise laboratory test confirms or rules out those results.
How Screening Works
The most common method is an immunoassay, a chemical test that reacts to drugs or their byproducts in your sample. It’s fast, relatively inexpensive, and can be done on-site as a point-of-care test. Results are qualitative, meaning they tell you whether a substance is present or absent, not how much is in your system.
Immunoassays are sensitive but not perfectly specific. They work by detecting chemical structures, and sometimes unrelated compounds look similar enough to trigger a false positive. Cough syrup containing dextromethorphan, for example, can produce a positive result for PCP. These tests also can’t distinguish between individual drugs within the same class, so they won’t tell the difference between different types of opiates or amphetamines.
When an initial screen comes back positive, the same sample typically goes to a laboratory for confirmatory testing using a technique called gas chromatography-mass spectrometry (GC-MS). This method identifies the exact substance and measures its concentration. False positives are rare with GC-MS because it isn’t susceptible to the cross-reactivity problems that affect immunoassays. The tradeoff is that it takes longer and costs more.
What Substances Are Tested
The traditional federal standard, sometimes called a 5-panel test, screens for five drug categories: marijuana, cocaine, opiates (like codeine and morphine), PCP, and amphetamines. As of mid-2025, the Department of Health and Human Services updated its mandatory guidelines for federal workplace testing to also include fentanyl and MDMA (ecstasy), reflecting the current drug landscape. Fentanyl’s urine cutoff is set extremely low at 1 ng/mL, far more sensitive than the thresholds for other substances, because even small amounts can be dangerous.
Employers outside the federal system can customize their panels. Some test for as few as four substances, while others use expanded panels that include benzodiazepines, barbiturates, synthetic opioids, or other drugs based on industry needs or regional trends.
Alcohol-Specific Screening
Alcohol leaves the body quickly, so the testing approach depends on whether the goal is catching current intoxication or detecting recent drinking. Breath alcohol tests measure how much alcohol is in your system right now and are commonly used in roadside stops and workplace post-accident testing. The result reflects your blood alcohol concentration at that moment.
For a longer detection window, tests look for a byproduct called EtG (ethyl glucuronide). EtG stays in urine or blood for one to two days after drinking, well after alcohol itself has been fully metabolized. When measured in hair samples, EtG can indicate drinking patterns over months, making it useful for courts or treatment programs monitoring long-term sobriety.
Sample Types and Detection Windows
The type of sample collected determines how far back a test can look.
- Urine is the most widely used. Most substances become detectable about two hours after use, and the window generally extends several hours to a few days. Heavy or chronic use can stretch detectability to several weeks.
- Blood has a short window of one to two days and is typically reserved for situations where current impairment matters, like post-accident testing.
- Saliva (oral fluid) detects most substances for up to 48 hours. Federal guidelines now authorize oral fluid testing as an alternative to urine for workplace programs, with its own set of cutoff levels.
- Hair provides the longest lookback. Scalp hair reflects roughly three months of exposure, while slower-growing body hair can indicate use up to 12 months prior.
- Sweat is collected via patches worn on the skin and can detect substances over a range of several hours to several weeks, making it useful for ongoing monitoring in probation or treatment settings.
Why Screening Is Ordered
The context shapes everything about how a screening is conducted and what happens with the results. In workplace settings, testing typically falls into a few categories: pre-employment screening before you start a job, random testing during employment, post-accident testing after a workplace incident, and reasonable-suspicion testing when a supervisor observes signs of impairment. Federal regulations under the Department of Transportation require all of these for safety-sensitive positions like commercial drivers, pilots, and transit operators. An employee who tests positive must be immediately removed from safety-sensitive duties.
In clinical settings, the purpose shifts from enforcement to care. Addiction treatment programs use testing to monitor abstinence and detect early relapse. Pain management clinics test patients to confirm they’re taking prescribed medications as directed and not using other controlled substances. The panels used in clinical testing tend to be broader and more tailored than the standard workplace five-panel, rotating based on what’s clinically relevant for that patient.
Legal and forensic screening, such as for court-ordered monitoring or child custody cases, carries the strictest procedural requirements. Confirmatory testing with GC-MS is considered essential in these situations, since a false positive from an immunoassay alone wouldn’t hold up.
The Chain of Custody Process
When test results carry legal or employment consequences, the collection follows a documented chain of custody to prove the sample wasn’t tampered with or mixed up. This process is more structured than what you’d experience at a routine doctor’s visit.
At the collection site, the collector checks your specimen’s temperature within four minutes to verify it’s fresh. They inspect it for unusual color, odor, or foreign material. You watch as the collector pours the specimen into labeled bottles, seals them, and dates the seals. You then initial those seals and sign a certification statement. The collector packages everything in a leak-proof bag along with the custody form, then ships it to the testing facility. At the lab, technicians verify the seals are intact before processing. Every hand the specimen passes through is documented on the same form.
Most regulated collections split the sample into two bottles. If the primary specimen tests positive, you have the right to request that the second bottle be tested at a different laboratory.
Common Causes of False Positives
False positives on initial immunoassay screens happen more often than most people realize, which is why confirmatory testing exists. Nasal decongestants containing pseudoephedrine can trigger a positive for amphetamines. Certain antidepressants, including bupropion (commonly prescribed for depression and smoking cessation), have been documented to produce false amphetamine results. Antihistamines, some antipsychotic medications, and even Vicks inhalers are also known to cause false positives.
If you’re taking any prescription or over-the-counter medications, you’ll typically have the opportunity to disclose them to a medical review officer (MRO) who evaluates positive results before they’re reported to your employer. The MRO’s job is to determine whether a legitimate medical explanation accounts for the result.
Marijuana Screening and Changing Laws
Twenty-four states and Washington, D.C., now allow recreational marijuana use, which has created a growing tension with workplace drug testing. Many of these states prohibit employers from disciplining or firing workers for legal, off-duty marijuana use. The core challenge is that drug tests detect the presence of marijuana metabolites in your system, not whether you’re currently impaired. THC metabolites can linger in urine for days or weeks after use, long after any psychoactive effects have worn off.
No state prevents employers from enforcing policies against being impaired on the job. But testing positive for marijuana is increasingly not considered proof of impairment. Federal employers and those in safety-sensitive industries regulated by the DOT still test for marijuana regardless of state laws, since it remains a federally controlled substance. For other employers, the legal landscape varies significantly by state and continues to shift.